Skip to main content

Table 1 ALK inhibitors discussed and their activity against various ALK resistance mutations

From: The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)

 

Drug

ALK Resistance Mutations

Crizontinib

Ceritinib

Alectinib

Brigatinib

Lorlatinib

L1196M

♦

•

•

•

 

G1269A

♦

•

•

•

 

S1206Y

♦

•

 

•

 

V1180L

♦

•

♦

•

 

G1202R

♦

♦

♦

♦

•

C1156Y

♦

♦

•

•

 

1151Tins

♦

♦

 

•

 

F1174C/L

♦

♦

•

•

 

L1152R/P

♦

♦ (L1152R)

 

•

 

L1198P

♦

  

• (L1198F)

 

I1171N/T

♦

•

♦

• (I1171N)

 

D1203N

♦

  

•

 
  1. ♦ Mutation confers resistance/insensitivity to the inhibitor
  2. • Inhibitor overcomes resistance mutation